

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Nakagawa T, Takeuchi S, Yamada T, Ebi H, Sano T, Nanjo S, Ishikawa D, Sato M, Hasegawa Y, Sekido Y, Yano S.	EGFR-TKI resistance due to BIM polymorphism can be circumvented by in combination with HDAC inhibition.	Cancer Res	73	2428-34	2013
Ando M, Kawazu M, Ueno T, Fukumura K, Yamato A, Soda M, Yamashita Y, Choi YL, Yamasoba T & Mano H., Ueno T, Fukumura K, Yamato A, Soda M, Yamashita Y, Choi YL, Yamasoba T & Mano H.	Cancer-associated missense mutations of caspase-8 activate nuclear factor-kappaB signaling.	Cancer Sci	104	1002-8	2013
Tominaga-Sato S, Imanishi D, Imaizumi Y, Iwanaga M, Itonaga H, Yoshida S, Hata T, Moriuchi R, Kiyoi H, Nimer S, Mano H, Naoe T, Tomonaga M, Miyazaki Y.	Mutations in the nucleolar phosphoprotein, nucleophosmin, promote the expression of the oncogenic transcription factor MEF/ELF4 in leukemia cells and potentiates transformation.	J Biol Chem	288	9457-67	2013
Kawazu M, Ueno T, Kontani K, Ogita Y, Ando M, Fukumura K, Yamato A, Soda M, Takeuchi K, Miki Y, Yamaguchi H, Yasuda T, Naoe T, Yamashita Y, Katada T, Choi YL, Mano H.	Transforming mutations of RAC guanosine triphosphatases in human cancers.	Proc Natl Acad Sci U S A	110	3029-34	2013
Suzuki HI, Matsuyama H, Noguchi M, Yao T, Komatsu N, Mano H, Sugimoto K, Miyazono K.	Computational dissection of distinct microRNA activity signatures associated with peripheral T cell lymphoma subtypes.	Leukemia	27	2107-11	2013
Yasuda T, Ueno T, Fukumura K, Yamato A, Ando M, Yamaguchi H, Soda M, Kawazu M, Sai E, Yamashita Y, Murata M, Kiyoi H, Naoe T, Mano H.	Leukemic evolution of donor-derived cells harboring IDH2 and DNMT3A mutations after allogeneic stem cell transplantation.	Leukemia	28	426-28	2014

Daito H, Suzuki M, Shiihara J, Kilgore PE, Ohtomo H, Morimoto K, et al.	Impact of the Tohoku earthquake and tsunami on pneumonia hospitalisations and mortality among adults in northern Miyagi, Japan: a multicentre observational study.	Thorax	68(6)	544-50	2013
Hagiwara K, Kobayashi K.	Importance of the cytological samples for the epidermal growth factor receptor gene mutation test for non-small cell lung cancer.	Cancer Sci	104(3)	291-7	2013
Kobayashi K, Hagiwara K.	Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC).	Target Oncol	8(1)	27-33	2013
Watanabe S, Minegishi Y, Yoshizawa H, Maemondo M, Inoue A, Sugawara S, et al.	Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.	J Thorac Oncol	9(2)	189-94	2014
Shindo Y, Ito R, Hasegawa Y et al.	Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia.	Am J Respir Crit Care Med	188(8)	985-95	2013
Yoshida K, Sato M, Hase T, Elshazley M, Yamashita R, Usami N, Taniguchi T, Yokoi K, Nakamura S, Kondo M, Girard L, Minna JD, Hasegawa Y.	TIMELESS is overexpressed in lung cancer and its expression correlates with poor patient survival.	Cancer Sci	104(2)	171-7	2013
Aoyama D, Hashimoto N, Sakamoto K, Kohnoh T, Kusunose M, Kimura M, Ogata R, Imaizumi K, Kawabe T, Hasegawa Y.	Involvement of TGFβ-induced phosphorylation of the PTEN C-terminus on TGFβ-induced acquisition of malignant phenotypes in lung cancer cells.	PLoS One	8(11)	e81133	2013

Fukatsu A, Ishiguro F, Tanaka I, Kudo T, Nakagawa K, Shinjo K, Kondo Y, Fujii M, Hasegawa Y, Tomizawa K, Mitsudomi T, Osada H, Hata Y, Sekido Y.	RASSF3 downregulation increases malignant phenotypes of non-small cell lung cancer.	Lung Cancer	83(1)	23-9	2013
Okamoto W, Yoshino T, Takahashi T, Okamoto I, Ueda S, Tsuya A, Boku N, Nishio K, Fukuoka M, Yamamoto N, Nakagawa K.	A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors.	Cancer Chemother Pharmacol	72(5)	1063-71	2013
Ono A, Takahashi T, Oishi T, Sugino T, Akamatsu H, Shukuya T, Taira T, Kenmotsu H, Naito T, Murakami H, Nakajima T, Endo M, Yamamoto N.	Acute lung injury with alveolar hemorrhage as adverse drug reaction related to crizotinib.	J Clin Oncol	31(26)	e417-9	2013
Hosokawa M, Kenmotsu H, Koh Y, Yoshino T, Yoshikawa T, Naito T, Takahashi T, Murakami H, Nakamura Y, Tsuya A, Shukuya T, Ono A, Akamatsu H, Watanabe R, Ono S, Mori K, Kanbara H, Yamaguchi K, Tanaka T, Matsunaga T, Yamamoto N.	Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system.	PLoS One	8(6)	e67466	2013
Tokito T, Shukuya T, Akamatsu H, Taira T, Ono A, Kenmotsu H, Naito T, Murakami H, Takahashi T, Endo M, Yamamoto N.	Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases.	Cancer Chemother Pharmacol	71(6)	1493-8	2013
Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, et al.	Efficacy and safety of the selective ALK inhibitor CH5424802/RO5424802 in patients with ALK-rearranged advanced non-small cell lung cancer: a phase I/II study (AF-001JP study).	Lancet Oncol	14	590-8	2013

Sugawara S, Maemondo M, Tachihara M, Inoue A, et al.	Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell Lung cancer : NJLCG 0601.	Lung Cancer	81	91-6	2013
Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, Tan EH, Ho JC, Chu da T, Zaatar A, Osorio Sanchez JA, Vu VV, Au JS, Inoue A, et al.	Impact of epidermal growth factor receptor inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.	J Natl Cancer I	105	595-605	2013
Sato S, Hanibuchi M, Kuramoto T, Yamamori N, Goto H, Ogawa H, Mitsuhashi A, Van TT, Kakiuchi S, Akiyama S, Nishioka Y, Sone S.	Macrophage stimulating protein promotes liver metastases of small cell lung cancer cells by affecting the organ microenvironment.	Clin Exp Metastasis	30	333-44	2013
Mitsuhashi A, Goto H, Kuramoto T, Tabata S, Yukishige S, Abe S, Hanibuchi M, Kakiuchi S, Saijo A, Aono Y, Uehara H, Yano S, Ledford JG, Sone S, Nishioka Y.	Surfactant protein A suppresses lung cancer progression by regulating the polarization of tumor-associated macrophages.	Am J Pathol	182	1843-53	2013
Abe S, Morita Y, Kaneko MK, Hanibuchi M, Tsujimoto Y, Goto H, Kakiuchi S, Aono Y, Huang J, Sato S, Kishuku M, Taniguchi Y, Azuma M, Kawazoe K, Sekido Y, Yano S, Akiyama S, Sone S, Minakuchi K, Kato Y, Nishioka Y.	A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody.	J Immunol	190	6239-49	2013
Huang J, Tabata S, Kakiuchi S, Van TT, Goto H, Hanibuchi M, Nishioka Y.	Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: a potential therapeutic target.	Oncotarget	4	1172-84	2013

Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, Ichinose Y, Kobayashi K, Takeda K, Kiura K, Nishio K, Seki Y, Ebisawa R, Shahidi M, Yamamoto N.	LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.	J Clin Oncol	31	3335-41	2013
Urata Y, Okamoto I, Takeda M., Hattori Y, Okuno K, Shimada T, Kurata T, Kaneda H, Miyazaki M, Terashima M, Tanaka K, Morita S, Nakagawa K, Negoro S, Satouchi M.	Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naïve patients with advanced nonsquamous non-small cell lung cancer.	Cancer	119(12)	2275-81	2013
Satouchi M., Okamoto I, Sakai H, Yamamoto N, Ichinose Y, Ohmatsu H, Nogami N, Takeda K, Mitsudomi T, Kasahara K, Negoro S.	Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer.	Lung Cancer	81(1)	97-101	2013
Yoshioka H, Okamoto I, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Atagi S, Hirashima T, Kudoh S, Satouchi M, Ikeda N, Iwamoto Y, Sawa T, Nakanishi Y, Nakagawa K.	Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology.	Ann Oncol	24(5)	1326-31	2013
Satouchi M, Kotani Y, Shibata T, Ando M, Nakagawa K, Yamamoto M, Ichinose Y, Ohe Y, Nishio M, Hida T, Takeda K, Kimura T, Minato K, Yokoyama A, Atagi S, Fukuda, H, Tamura T, Saijo N.	Phase III study comparing irinotecan plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509.	J Clin Oncol		In press	2014

Tsujino K, Kurata T, Yamamoto S, Kawaguchi T, Kubo A, Isa S, Hasegawa Y, Ou SH, Takada M, Ando M.	Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small cell lung cancer? A pooled analysis of the literature.	J Thorac Oncol	8	1181-9	2013
Yoshioka H, Okamoto I, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, HideoSaka, Asami K, Hirashima T, Kudoh S, Satouchi M, Ikeda N, Iwamoto Y, Sawa T, Nakanishi Y, Nakagawa K.	Efficacy and safety analysis by histology of S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer: Updated results of a West Japan Oncology Group LETS study.	Ann Oncol	24	1326-31	2013
Kogure Y, Ando M, Saka H, Chiba Y, Yamamoto N, Asami K, Hirashima T, Seto T, Nagase S, Otsuka K, Yanagihara K, Takeda K, Okamoto I, Aoki T, Takayama K, Yamasaki M, Kudoh S, Katakami N, Miyazaki M, Nakagawa K.	Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer: Results of West Japan Oncology Group (WJOG) Study 3906L.	J Thorac Oncol	8	753-8	2013